Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Inform ; 39(7): e1900165, 2020 07.
Article in English | MEDLINE | ID: mdl-32078760

ABSTRACT

Based on the finding that a central antihypertensive agent with high affinity for I1-type imidazoline receptors - rilmenidine, shows cytotoxic effects on cultured cancer cell lines, it has been suggested that imidazoline receptors agonists might have a therapeutic potential in the cancer therapy. Nevertheless, potential rilmenidine side effects caused by activation of α-adrenoceptors, or other associated receptors and enzymes, might hinder its therapeutic benefits. Considering that human α-adrenoceptors belong to the rhodopsin-like class A of G-protein-coupled receptors (GPCRs) it is reasonable to assume that imidazolines might have the affinity for other receptors from the same class. Therefore, to investigate possible off-target effects of imidazoline ligands we have prepared a reverse docking protocol on class A GPCRs, using imidazoline ligands and their decoys. To verify our in silico results, three ligands with high scores and three ligands with low scores were tested for antagonistic activity on α2 - adrenoceptors.


Subject(s)
Imidazolines/chemistry , Receptors, G-Protein-Coupled/metabolism , Animals , Area Under Curve , Benzofurans/chemistry , Benzofurans/pharmacology , CHO Cells , Cricetulus , Humans , Idazoxan/chemistry , Idazoxan/pharmacology , Imidazoles/chemistry , Imidazoles/pharmacology , Imidazolines/pharmacology , Ligands , Molecular Docking Simulation , Receptors, Adrenergic, alpha-2/metabolism , Reproducibility of Results
2.
Acta Neuropsychiatr ; 27(6): 345-52, 2015 Dec.
Article in English | MEDLINE | ID: mdl-25903810

ABSTRACT

OBJECTIVES: Disturbances in the noradrenergic system, including alterations in the densities of α2-adrenoceptors, are posited to be involved in the pathophysiology of depression. In this study, we investigate the binding of α2-adrenoceptors in regions relevant to depression in an animal model of depression. METHODS: Using in vitro autoradiography techniques and the selective α2-ligand, [3H]RX 821002, we investigated the density of α2-adrenoceptors in female Flinders-sensitive line (FSL) rats, a validated model of depression, and in two traditional control groups - female Flinders-resistant line (FRL) and Sprague-Dawley (SD) rats. RESULTS: The α2-adrenoceptor density was increased in most regions of the FSL rat brain when compared with SD rats (10% across regions). Moreover, the α2-adrenoceptor density was further increased in the FRL rats compared with both FSL (10% across regions) and SD rats (24% across regions). CONCLUSIONS: The increase in α2-adrenoceptor binding in cortical regions in the FSL strain compared with the SD control strain is in accord with α2-adrenoceptor post-mortem binding data in suicide victims with untreated major depression. However, the differences in binding observed in the two control groups were unexpected and suggest the need for further studies in a larger cohort of animals of both sexes.


Subject(s)
Adrenergic Neurons/metabolism , Brain/metabolism , Depression/metabolism , Receptors, Adrenergic, alpha-2/metabolism , Adrenergic alpha-Antagonists/chemistry , Animals , Autoradiography/methods , Disease Models, Animal , Female , Idazoxan/analogs & derivatives , Idazoxan/chemistry , Protein Binding , Rats , Rats, Sprague-Dawley
3.
Bioorg Med Chem ; 20(7): 2259-65, 2012 Apr 01.
Article in English | MEDLINE | ID: mdl-22370341

ABSTRACT

Aim of the present study was to obtain novel α(2)-adrenoreceptor (α(2)-AR) antagonists, possibly endowed with subtype-selectivity. Therefore, inspired by the non subtype-selective α(2)-AR antagonist idazoxan, we designed 1,4-dioxane derivatives bearing an aromatic area in position 5 or 6 and the imidazoline nucleus in position 2. Among the novel molecules 1-6, compound 2, with a trans stereochemical relationship between 5-phenyl and 2-imidazoline groups, was able to antagonize the sole α(2A)-subtype. Moreover, 2 showed an affinity at I(2)-imidazoline binding sites (I(2)-IBS) comparable to that at α(2A)-AR. In in vivo studies 2 strongly increased morphine analgesia. This interesting behaviour appeared to be induced by the favourable involvement of α(2A)-AR antagonism in the I(2)-IBS-mediated morphine analgesia enhancement.


Subject(s)
Adrenergic alpha-2 Receptor Antagonists/chemistry , Imidazolines/chemistry , Receptors, Adrenergic, alpha-2/chemistry , Adrenergic alpha-2 Receptor Antagonists/chemical synthesis , Adrenergic alpha-2 Receptor Antagonists/pharmacology , Animals , Binding Sites , Humans , Idazoxan/chemistry , Male , Mice , Morphine/pharmacology , Pain Measurement/drug effects , Receptors, Adrenergic, alpha-2/metabolism , Stereoisomerism
4.
Proc Natl Acad Sci U S A ; 104(24): 9982-7, 2007 Jun 12.
Article in English | MEDLINE | ID: mdl-17535904

ABSTRACT

Arginine contains the guanidinium group and thus has structural similarity to ligands of imidazoline and alpha-2 adrenoceptors (alpha-2 AR). Therefore, we investigated the possibility that exogenous arginine may act as a ligand for these receptors in human umbilical vein endothelial cells and activate intracellular nitric oxide (NO) synthesis. Idazoxan, a mixed antagonist of imidazoline and alpha-2 adrenoceptors, partly inhibited L-arginine-initiated NO formation as measured by a Griess reaction. Rauwolscine, a highly specific antagonist of alpha-2 AR, at very low concentrations completely inhibited NO formation. Like L-arginine, agmatine (decarboxylated arginine) also activated NO synthesis, however, at much lower concentrations. We found that dexmedetomidine, a specific agonist of alpha-2 AR was very potent in activating cellular NO, thus indicating a possible role for alpha-2 AR in L-arginine-mediated NO synthesis. D-arginine also activated NO production and could be inhibited by imidazoline and alpha-2 AR antagonists, thus indicating nonsubstrate actions of arginine. Pertussis toxin, an inhibitor of G proteins, attenuated L-arginine-mediated NO synthesis, thus indicating mediation via G proteins. L-type Ca(2+) channel blocker nifedipine and phospholipase C inhibitor U73122 inhibited NO formation and thus implicated participation of a second messenger pathway. Finally, in isolated rat gracilis vessels, rauwolscine completely inhibited the L-arginine-initiated vessel relaxation. Taken together, these data provide evidence for binding of arginine to membrane receptor(s), leading to the activation of endothelial NO synthase (eNOS) NO production through a second messenger pathway. These findings provide a previously unrecognized mechanistic explanation for the beneficial effects of L-arginine in the cardiovascular system and thus provide new potential avenues for therapeutic development.


Subject(s)
Arginine/pharmacology , Endothelial Cells/enzymology , Endothelial Cells/metabolism , Nitric Oxide/biosynthesis , Receptors, Adrenergic, alpha-2/metabolism , Adrenergic alpha-Antagonists/pharmacology , Agmatine/chemistry , Agmatine/pharmacology , Aniline Compounds , Arginine/antagonists & inhibitors , Arginine/chemistry , Calcium/analysis , Calcium Channel Blockers/pharmacology , Cell Culture Techniques , Cells, Cultured , Culture Media, Serum-Free , Dexmedetomidine/pharmacology , Dose-Response Relationship, Drug , Endothelial Cells/cytology , Endothelium, Vascular/cytology , Enzyme Activation/drug effects , Estrenes/pharmacology , Fluorescent Dyes , Humans , Idazoxan/chemistry , Idazoxan/pharmacology , Imidazolines/pharmacology , Lipopolysaccharides/pharmacology , Molecular Structure , NG-Nitroarginine Methyl Ester/pharmacology , Nifedipine/pharmacology , Nitrates/analysis , Nitric Oxide/antagonists & inhibitors , Nitric Oxide Synthase Type III/metabolism , Nitrites/analysis , Pyrrolidinones/pharmacology , Second Messenger Systems/physiology , Type C Phospholipases/antagonists & inhibitors , Umbilical Veins/cytology , Virulence Factors, Bordetella/pharmacology , Xanthenes , Yohimbine/pharmacology
5.
Eur J Pharmacol ; 553(1-3): 73-81, 2006 Dec 28.
Article in English | MEDLINE | ID: mdl-17081513

ABSTRACT

Some studies, suggesting the involvement of I(2)-imidazoline binding sites (I(2)-IBS) in morphine analgesia modulation, prompted us to examine on mice antinociceptive assays the effect produced by 1 (phenyzoline), that in view of its high I(2)-IBS affinity and high I(2)-IBS selectivity with regard to I(1)-IBS, alpha(2)-adrenoreceptors and mu-opioid receptors might be considered the first interesting I(2)-IBS ligand. The study was also applied to its ortho phenyl derivative 2 (diphenyzoline), designed and prepared in order to produce a possible modification of the biological profile of 1. Diphenyzoline (2) retains a significant I(2)-IBS selectivity with regard to I(1)-IBS, alpha(2)-adrenoreceptors and mu-opioid receptors. Moreover, by the functional assays 1 and 2 proved inactive at all alpha(2)-adrenoreceptors subtypes up to 10(-3) M. As expected, phenyzoline and diphenyzoline, which are structurally related, highlighted an interesting "positive" or "negative", respectively, morphine analgesia modulatory effect. In fact, 1 (s.c. 10 mg/kg) enhanced morphine analgesia (60% and 40% in mouse tail-flick and mouse hot-plate, respectively), while 2 (s.c. 10 mg/kg) decreased it (-41% and -20%, respectively). The ability to decrease morphine analgesia had never been observed before in I(2)-IBS ligands. These effects were not affected by i.p. treatment of animals with yohimbine (a selective alpha(2)-adrenoreceptor antagonist, 0.625 mg/kg) or efaroxan (an I(1)-IBS/alpha(2)-adrenoreceptor antagonist, 1.0 mg/kg). In contrast, they were completely reversed by i.p. treatment of animals with idazoxan (an I(2)-IBS/alpha(2)-adrenoreceptor antagonist, 2 mg/kg). Moreover, compound 2, in mouse tail-flick test, was able to potentiate by 23% the naloxone-induced decrease of morphine analgesia. Therefore, the results of this study indicate the crucial involvement of I(2)-IBS in the morphine analgesia modulatory effects of 1 and 2.


Subject(s)
Analgesics, Opioid/pharmacology , Morphine/pharmacology , Receptors, Drug/metabolism , Adrenergic alpha-Antagonists/chemistry , Adrenergic alpha-Antagonists/pharmacology , Animals , Benzofurans/pharmacology , CHO Cells , Cricetinae , Idazoxan/chemistry , Idazoxan/pharmacology , Imidazoles/chemistry , Imidazoles/pharmacology , Imidazoline Receptors , Male , Mice , Models, Molecular , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Pain Measurement/drug effects , Radioligand Assay , Reaction Time/drug effects , Receptors, Adrenergic, alpha-2/drug effects , Receptors, Drug/chemistry , Receptors, Drug/drug effects , Receptors, Opioid, mu/drug effects , Yohimbine/pharmacology
6.
Synapse ; 55(2): 126-32, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15543627

ABSTRACT

Noradrenaline plays an important role in many normal brain functions, e.g., attention, memory, and emotion. Dysfunction in the noradrenergic system is thought to lead to a number of abnormal brain conditions. The lack of suitable in vivo tracers to monitor noradrenaline release, levels, and regulation has hampered our fully understanding the roles that it plays in the brain. Presented here are data showing that the in vivo binding of the alpha2-adrenoceptor antagonist [3H]RX 821002 is sensitive to endogenous noradrenaline. Elevation of extracellular noradrenaline, using three different pharmacological challenges in rat, led to a reduction in the binding potential (BP) of [3H]RX 821002 when compared with vehicle controls. The challenges used were i.p. administration of D-amphetamine, the imidazoline2 binding site-selective ligand BU224, and L-deprenyl. Of the cortical regions measured, the reduction in BP reached significance in the anterior cingulate cortex for all of these pharmacological challenges. These initial observations in rat indicate that labelling of the alpha2-adrenoceptors with RX 821002 can be used to estimate changes in extracellular noradrenaline concentration in the cortex. This has the potential to enable the investigation of the role that noradrenaline plays both in the normal and abnormal brain and, if the ligand can be radiolabelled with a suitable positron-emitting isotope at high specific radioactivity, it could be an invaluable PET tracer.


Subject(s)
Adrenergic alpha-Antagonists/pharmacokinetics , Brain/metabolism , Idazoxan/analogs & derivatives , Idazoxan/pharmacokinetics , Norepinephrine/metabolism , Adrenergic Uptake Inhibitors/pharmacology , Adrenergic alpha-Antagonists/chemistry , Animals , Binding, Competitive/drug effects , Brain/anatomy & histology , Brain/drug effects , Dextroamphetamine/pharmacology , Idazoxan/chemistry , Imidazoles/pharmacology , Male , Microdialysis/methods , Monoamine Oxidase Inhibitors/pharmacology , Radioligand Assay/methods , Rats , Rats, Wistar , Selegiline/pharmacology , Time Factors , Tissue Distribution , Tritium/pharmacokinetics
7.
Arch Physiol Biochem ; 111(2): 159-66, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12919003

ABSTRACT

The imidazoline-type compound, MPV-1743, has been found to activate nonshivering thermogenesis (NST) in brown adipose tissue (BAT) of the genetically obese Zucker rats. The regulation of NST in BAT is linked to the catecholamine metabolism, and the imidazoline I2-binding sites have been found on the monoamine oxidase, a catecholamine metabolising enzyme. In this study, the I2-binding sites of hamster BAT have been characterised using a receptor binding assay with 3H-idazoxan as a radioligand, and the interaction of MPV-1743 with these I2-binding sites has been studied using the enantiomers of MPV 1743, that is, MPV 2088 and MPV 2089. Cirazoline was used to determine the specific binding of 3H-idazoxan to the imidazoline I2-binding sites. Rauwolscine was added in the 3H-idazoxan binding assay in order to inhibit any binding to potential alpha2-adrenergic sites. In the presence of rauwolscine mask 3H-Idazoxan labelled a population of non-adrenergic binding sites expressing the properties of the imidazoline I2b-receptor subtype similar to that found in the rat liver (cirazoline >> guanabenz = amiloride >> clonidine). The binding of 3H-idazoxan to the I2b-binding sites could be displaced by the imidazole compounds with the following affinities: detomidine (KiHigh 9.2 nM; KiLow 3200 nM), MPV-2088 (KiHigh 19 nM; IKiLow 760 nM) and MPV-2089 (KiHigh 190 nM; KiLow 1300 nM), atipamezole (3500 nM) and dexmedetomidine (Ki 8400 nM). These results have shown that the hamster BAT contains the imidazoline I2b-binding sites with heterogeneous binding properties for some test compounds. In addition, the enantiomers of MPV 1743, that is, MPV 2088 and MPV 2089, had high affinity to these BAT imidazoline I2b-binding sites. Therefore, it is suggested that the regulation of NST in the hamster BAT may be an attractive model to study the role of imidazoline I2b-binding sites.


Subject(s)
Adipose Tissue, Brown/chemistry , Adipose Tissue, Brown/metabolism , Idazoxan/pharmacokinetics , Receptors, Drug/chemistry , Receptors, Drug/metabolism , Amiloride/chemistry , Amiloride/pharmacokinetics , Animals , Binding Sites , Binding, Competitive , Cell Line, Tumor , Clonidine/chemistry , Clonidine/pharmacokinetics , Culture Techniques , Dose-Response Relationship, Drug , Guanabenz/chemistry , Guanabenz/pharmacokinetics , Humans , Idazoxan/chemistry , Imidazoles/chemistry , Imidazoles/pharmacokinetics , Imidazoline Receptors , Liver/chemistry , Liver/metabolism , Mammary Neoplasms, Animal , Mice , Protein Binding , Rats , Species Specificity , Yohimbine/chemistry , Yohimbine/pharmacokinetics
8.
Neurochem Int ; 30(1): 47-53, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9116587

ABSTRACT

Using radioligand binding techniques, several compounds selective for mammalian brain imidazoline 2 receptors have been identified. In rabbit brain membranes, a series of 6 and/or 7 aromatic-substituted derivatives of the alpha 2-adrenoceptor antagonist idazoxan were found to show moderate affinity for I2 receptors over alpha 2-adrenoceptors, in particular 6,7-dichloroidazoxan, which was 41 fold selective in favour of I2 receptors. Modification of the benzodioxan ring of idazoxan could also result in affinity and selectivity, which was moderate (2.7 nM, 161 fold) in the case of the 1,3-benzodioxan isomer of idazoxan (2-(1,3-benzodioxanyl)-2-imidazoline), and high (1.3 nM, 2873 fold) in the case of 2-(2-benzofuranyl-2-imidazoline) (2-BFI). Analogues of 2-BFI with halogenic substitutions of the aromatic ring were also found to retain high affinity and moderate to high selectivity for I2-sites. In particular, the 7-chloro (Ki 2.8 nM, 2192 fold) and the 4,6-dibromo (Ki 6.1 nM, 361 fold) analogues of 2-BFI. These new ligands should prove invaluable for investigating the pharmacology and physiology of I2 receptors.


Subject(s)
Receptors, Drug/metabolism , Adrenergic alpha-Antagonists/metabolism , Animals , Benzofurans/chemistry , Benzofurans/metabolism , Brain/metabolism , Cell Membrane/metabolism , Female , Idazoxan/analogs & derivatives , Idazoxan/chemistry , Idazoxan/metabolism , Imidazoline Receptors , Ligands , Male , Rabbits , Radioligand Assay , Receptors, Adrenergic, alpha/metabolism , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...